Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Tetragon Biosciences Ltd
Washington University School of Medicine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NRG Oncology
Trogenix ltd
University of Aberdeen
The Cooper Health System
Lantern Pharma Inc.
Northwestern University
Jonsson Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medical University of Warsaw
VA Office of Research and Development
University Hospital, Essen
University of Texas Southwestern Medical Center
Washington University School of Medicine
University of California, San Francisco
University of Cincinnati
Hospital del Rio Hortega
CRISM Therapeutics LTD
Swansea Bay University Health Board
ZSky Biotech Inc
Leica Microsystems (Schweiz) AG
Everfront Biotech Co., Ltd.